Targeting a specific process in childhood brain tumors
Targeting Transcriptional Elongation in Pediatric Glioma
This study is looking at a tough type of brain cancer in kids called DIPG to find better ways to treat it by exploring how certain gene changes affect the tumors, with the hope of improving survival for children facing this illness.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11053567 on NIH RePORTER |
What this research studies
This research focuses on diffuse intrinsic pontine glioma (DIPG), a severe type of brain cancer in children. It aims to identify effective treatment targets by studying the molecular characteristics of DIPG, particularly the role of certain gene mutations. The researchers are using advanced techniques like CRISPR/Cas9 to explore new therapeutic strategies and combinations that could improve treatment outcomes and delay resistance to existing therapies. By understanding how these tumors develop and respond to treatments, the goal is to enhance survival rates for affected children.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 diagnosed with diffuse intrinsic pontine glioma.
Not a fit: Patients with other types of brain tumors or those outside the specified age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for children with DIPG, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promise in targeting similar molecular pathways in pediatric cancers, indicating potential for success in this approach.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Hashizume, Rintaro — University of Alabama at Birmingham
- Study coordinator: Hashizume, Rintaro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.